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Immune  reconstitution  inﬂammatory  syndrome  (IRIS)  is  a  phenomenon  that  can  occur  when
a  patient’s  immune  system  recovers  after  a  period  of  immunodeﬁciency.  There  are  distinct
types  following  the  recovery  periods  from  different  kinds  of  immunodeﬁciency,  e.g.  a
patient  undergoing  antiretroviral  treatment  for  HIV,  recovering  from  post-chemotherapy
aplasia,  or  stopping  an  immunosuppressant  treatment.  We  report  a  case  of  a  patient  who
developed  IRIS  after  progressive  multifocal  leukoencephalopathy  within  multiple  sclerosis
(MS)  and  on  discontinuing  natalizumab.  We  discuss  the  contribution  made  by  the  brain  MRI
in  diagnosing  IRIS.
Case report
A  33-year-old  male  patient  had  been  under  monitoring  for  MS  for  8  years,  and  he  had
been  treated  with  mitoxantrone,  followed  by  interferon  beta-1a,  then  natalizumab  for
the  past  year.  Further  to  an  episode  when  he  was  unable  to  recall  words,  a  repeat  brain
MRI  was  carried  out  (Fig.  1).  The  white  matter  lesions  were  larger  than  they  had  been  on
the  previous  MRI  scan  (Fig.  2).  A  lumbar  puncture  was  carried  out  and  the  polyomavirus  JC
virus  was  identiﬁed  in  the  cerebrospinal  ﬂuid  (CSF)  on  PCR,  which  suggested  a diagnosis
of  progressive  multifocal  leukoencephalopathy  (PML)  and  this  meant  that  natalizumab  had
to  be  discontinued.
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Figure 1. Initial brain MRI. Transverse axial views using Fluid-Attenuated Inversion Recovery (FLAIR) and T1 SE (spin echo) sequences, both
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The  patient  was  treated  with  plasmapheresis  for  PML,
n  order  to  reduce  the  serum  concentration  of  natalizumab
nd  reduce  his  immunosuppression,  and  he  also  received
irtazapine  and  meﬂoquine.  Shortly  after  the  plasmaphere-
is,  the  patient  presented  status  epilepticus  and  he  needed
o  be  admitted  to  hospital  in  the  intensive  care  ward.  In
ddition  to  aphasia,  the  clinical  examination  found  frontal
obe  syndrome,  lower  limb  motor  difﬁculties  and  sphincter
ysfunction  with  urinary  incontinence.  Several  differential
iagnoses  were  considered:  a  progression  of  his  PML,  side
igure 2. Previous brain MRI using Fluid-Attenuated Inversion
ecovery (FLAIR) sequences — same views.
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bal intensity on FLAIR sequences in the bilateral frontal and parietal
s in the white matter. Gadolinium-enhancing nodules present.
ffects  due  to  mirtazapine  and/or  meﬂoquine  toxicity,  or
RIS.
A  further  brain  MRI  was  carried  out.  It  showed  mul-
iple  high  signal  intensities  on  T2-FLAIR  imaging  in  the
eri-ventricular  white  matter  bilaterally,  which  were  nodu-
ar  and  presented  enhancement  after  use  of  a  contrast
gent  (Fig.  3),  suggesting  IRIS.  Treatment  was  initiated  with
igh-dose  corticosteroids,  which  led  to  improvement  in  his
linical  signs  thus  conﬁrming  the  diagnosis  of  IRIS.
iscussion
RIS  is  classically  seen  to  develop  in  23%  of  cases  of  HIV-
ositive  patients  with  PML  [1].  It  occurs  during  the  passage
rom  a  state  of  acquired  and  reversible  immunodeﬁciency
o  a state  of  functional  immunity  and  is  caused  by  stopping
n  immunosuppressant  treatment  or  starting  a  treatment
or  infection.  IRIS  seems  to  be  the  result  of  an  explo-
ive  immune  response  caused  by  excessive  stimulation  of
D8+  T-lymphocytes.  In  this  case  of  JC  virus  infection,
he  fall  in  the  concentration  of  natalizumab  induced  by
lasmapheresis  led  to  a  massive  increase  in  the  concentra-
ion  of  CD4+  and  CD8+  T-lymphocytes  in  the  CSF  [2].  The
trong  inﬂammatory  activity  of  the  MS  before  natalizumab
as  initiated  and  may  have  encouraged  IRIS  to  develop
3].
The  brain  MRI  scan  is  an  essential  tool  in  the  diagnosis  of
RIS  after  discontinuation  of  natalizumab  in  a  patient  with
ML.  It  demonstrates  lesions  in  the  peri-ventricular  white
atter  producing  high  signal  intensity  on  FLAIR  imaging  that
re  nodule-shaped  and  bilateral.  These  can  be  differenti-
ted  from  the  PML  lesions  because  they  are  much  more
idespread,  nodular,  and  they  present  a  greater,  patchier,
nd  more  diffuse  uptake  of  contrast  because  the  blood-
rain  barrier  is  disrupted.  IRIS  lesions  are  more  often  found
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Figure 3. Brain MRI after the episode of status epilepticus. Transverse axial views using Fluid-Attenuated Inversion Recovery (FLAIR) and
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signal intensities on FLAIR sequences in the peri-ventricular white m
at  the  peripheries  of  the  plaques  of  demyelination  that
existed  before  treatment  [3].  The  lesions  only  take  up
contrast  temporarily  and  this  phenomenon  is  not  seen  on
repeat  examinations.  [4].  These  signs  may  be  accompanied
by  diffuse  cerebral  oedema  that  could  lead  to  intracra-
nial  hypertension  and  life-threatening  brain  herniation.  PML
that  develops  after  treatment  with  natalizumab  can  be
differentiated  from  the  classic  presentation  of  PML  in  HIV-
positive  patients  because  the  lesions  are  more  invasive  and
contrast  uptake  occurs  more  frequently.  Lesion  enhance-
ment  can  even  be  found  before  natalizumab  is  discontinued,
and  this  phenomenon  is  considered  to  be  early  stage  IRIS
[5].  The  treatment  for  IRIS  is  high-dose  corticosteroid
therapy  [6].
Conclusion
This  case  report  emphasises  the  value  of  close  radiologi-
cal  monitoring  of  patients  with  MS  who  then  develop  PML
after  treatment  with  natalizumab  is  discontinued,  and  all
the  more  so  when  there  are  clinical  signs.  Combined  with
the  clinical  examination  and  PCR  analysis  of  the  CSF  (to
look  for  JC  virus),  use  of  radiology  can  guide  the  diagno-
sis  towards  IRIS  and  is  able  to  exclude  a  diagnosis  of  PML
disease  progression.ement. Appearance of multiple bilateral and nodule-shaped high
r (a). These nodules are gadolinium-enhancing (b, c).
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